June 8, the medical website 

 

General case 

 

The number of approvals in the first and April months was down 

 

In march and April 2017, the vaccine batches were 74.68 million. Compared with the same period in 2016, the trend is declining. Overall, the decline was about 37 per cent year-on-year, down about 42 per cent year-on-year in March and 26 per cent in April. 

 

 

 

2, the number of vaccine batches of the second class increased 

 

In march and April 2017, the total number of vaccines issued in the second category was 34.18 million, slightly less than one type of vaccine. Of those, the second category accounted for 46% of the vaccine approvals in March, compared with 41% in April. 2 kinds of vaccine in 2016 shandong vaccine event after the downturn in the situation, the enterprise production sales situation gradually restored, compared with the same period in 2016, 2 kinds of vaccines than rose. 

 

 

 

The vaccine batch domestic enterprise occupies the main body 

 

In April 2016, 2017, 3 - group signed a vaccine, rabies vaccine, hepatitis b vaccine, pertussis, diphtheria, tetanus vaccine varieties is given priority to, such as therelease of domestic enterprises accounted for the vast majority of proportion. 

 

 

 

There are three state-owned enterprises, and wuhan is in the lead 

 

In march and April, the first five companies were domestic enterprises. Three state-owned enterprises, two private enterprises. In addition to dalian hanxin bio-pharmaceutical co., LTD., only a single variety of hepatitis b vaccine is approved, and the other enterprises have three or more varieties. 

 

The largest batch of all four vaccine varieties in wuhan, the largest batch of Chinese products, was approved for approval. Among them, there were 6.45 million new batches of uncellular white and white vaccine. In wuhan, the adsorption of no cells with no cells is a new product of the whole cell. 

 

 

 

The rabies vaccine is made of 10 million varieties 

 

In march and April, vaccine batches of 10 million vaccine varieties have rabies vaccine and hepatitis b vaccine. Increased demand for vaccines is due to the increase in the number of attacks and the two-child policy in the spring season. The need for rabies vaccine and hepatitis b vaccine is increasing. 

 

 

 

Rabies vaccine: the replacement trend of freeze-dried preparations is obvious 

 

A total of 13.74 million rabies were issued in March and April, with the proportion of freeze-dried agents up to 94 percent. In recent years, the tendency of rabies vaccine to replace the normal dosage is obvious. 

 

The rabies vaccine used in our country is mainly supplied by changchun, ningbo rongan organism and liaoning chengda. Changchun's long-living creatures were signed up to 6.36 million units in March to April, a 59 percent increase from January to February. The second is ningbo rongan biology, with 374, 000 in March and April. Amount of rabies vaccine group signed in recent years topped the liaoning cheng da biological effect is serious by related events in 16 years, the number of sign the amount recovered in 2017, 3 to 4 months of signing capacity is 2.76 million, 72% growth from 1 to 2 months. 

 

 

 

 

Hepatitis b vaccine: a class of vaccine batches is equally in the autumn color 

 

In the three months to April, the number of vaccine varieties of hepatitis b vaccine was 54%, while the second category accounted for 46%. One type of vaccine is mainly supplied by dalian hanxin, which is supplied by shenzhen kangtai biology, north China pharmaceutical jintan and GSK. 

 

The dalian hanshin creature was a type of vaccine in 3-4 months, with a total of 4.99 million. The shenzhen kangtai biology has been gradually getting rid of the market slump caused by the vaccine, with 17 million in the first four months of 2017, up 96 percent from the same period in 2016. In the three months to April, the number of batches issued was 395, 000, all of which were type 2 vaccine varieties. 

 

 

 

The vaccine: wuhan is the most dominant 

 

In march and April, the companies that issued the baibai vaccine approvals were the wuhan institute of biological products and the sanofi Pasteur. Wuhan accounts for nearly 96% of the total. Both companies have seen a significant rise in the number of approvals from January to February. 

 

 

 

Measles, mumps and rubella vaccine: the Beijing temple of heaven accounts for over 40 percent 

 

Four vaccine manufacturers issued the vaccine in March and April for measles, mumps and rubella vaccine. Among them, the Beijing temple of heaven has the highest number of 2130,000 batches, accounting for over 40% of the total. Beijing tiantan biological production of ma gills wind rubella vaccine for domestic initiative, developed by our own attenuated measles and rubella vaccine, is domestic first licensed production and business operation entity. Second, the proportion was 28 per cent and 21 per cent respectively. The above production enterprises have both increased their monthly sales in January and February. 

 

 

 

LAN sheng is the leading brain vaccine 

 

In march and April, five vaccine manufacturers were issued in batches of the vaccine. As the absolute frontrunner for the group A group C meningococcal polysaccharide, lansheng was ranked first in the 1.35 million batch, with A decrease in the first month of the month. Of the four other companies, wuhan and changchun have no brain vaccine to issue the vaccine in January and February. Yuxi Watson has seen a decrease in the number of shipments from January to February, while Beijing's green bamboo has risen slightly.